Literature DB >> 9751722

pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation.

O Iliopoulos1, M Ohh, W G Kaelin.   

Abstract

The von Hippel-Lindau (VHL) gene encodes a protein consisting of 213 amino acid residues with an apparent molecular mass of 30 kDa (pVHL30). Here we show that cells also produce a VHL protein (pVHL19) that appears to arise as a result of internal translation from the second methionine within the VHL ORF. pVHL30 resides primarily in the cytosol, with less amounts found in the nucleus or associated with cell membranes. In contrast pVHL19, in biochemical fractionation experiments, is equally distributed between the nucleus and cytosol and is not found in association with membranes. pVHL19, like pVHL30, can bind to elongin B, elongin C, and Hs-Cul2 in coimmunoprecipitation assays and can inhibit the production of hypoxia-inducible proteins such as vascular endothelial growth factor (VEGF) and GLUT1 when reintroduced into renal carcinoma cells that lack a wild-type VHL allele. Thus, cells contain two biologically active VHL gene products.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751722      PMCID: PMC21697          DOI: 10.1073/pnas.95.20.11661

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

Review 1.  Cap-independent translation and internal initiation of translation in eukaryotic cellular mRNA molecules.

Authors:  N Iizuka; C Chen; Q Yang; G Johannes; P Sarnow
Journal:  Curr Top Microbiol Immunol       Date:  1995       Impact factor: 4.291

2.  SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box.

Authors:  C Bai; P Sen; K Hofmann; L Ma; M Goebl; J W Harper; S J Elledge
Journal:  Cell       Date:  1996-07-26       Impact factor: 41.582

3.  Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.

Authors:  S Lee; D Y Chen; J S Humphrey; J R Gnarra; W M Linehan; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

4.  Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations.

Authors:  T Kishida; T M Stackhouse; F Chen; M I Lerman; B Zbar
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

5.  Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.

Authors:  G Siemeister; K Weindel; K Mohrs; B Barleon; G Martiny-Baron; D Marmé
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

6.  The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix.

Authors:  M Ohh; R L Yauch; K M Lonergan; J M Whaley; A O Stemmer-Rachamimov; D N Louis; B J Gavin; N Kley; W G Kaelin; O Iliopoulos
Journal:  Mol Cell       Date:  1998-06       Impact factor: 17.970

7.  Tumour suppression by the human von Hippel-Lindau gene product.

Authors:  O Iliopoulos; A Kibel; S Gray; W G Kaelin
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

8.  Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations.

Authors:  D R Duan; J S Humphrey; D Y Chen; Y Weng; J Sukegawa; S Lee; J R Gnarra; W M Linehan; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

9.  Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.

Authors:  A Kibel; O Iliopoulos; J A DeCaprio; W G Kaelin
Journal:  Science       Date:  1995-09-08       Impact factor: 47.728

10.  Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II.

Authors:  T Aso; W S Lane; J W Conaway; R C Conaway
Journal:  Science       Date:  1995-09-08       Impact factor: 47.728

View more
  72 in total

Review 1.  HIF hydroxylation and the mammalian oxygen-sensing pathway.

Authors:  Michal Safran; William G Kaelin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

2.  Proteomic dissection of the von Hippel-Lindau (VHL) interactome.

Authors:  Yanlai Lai; Meihua Song; Kevin Hakala; Susan T Weintraub; Yuzuru Shiio
Journal:  J Proteome Res       Date:  2011-10-11       Impact factor: 4.466

3.  The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity.

Authors:  Daniel E Foxler; Katherine S Bridge; Victoria James; Thomas M Webb; Maureen Mee; Sybil C K Wong; Yunfeng Feng; Dumitru Constantin-Teodosiu; Thorgunnur Eyfjord Petursdottir; Johannes Bjornsson; Sigurdur Ingvarsson; Peter J Ratcliffe; Gregory D Longmore; Tyson V Sharp
Journal:  Nat Cell Biol       Date:  2012-01-29       Impact factor: 28.824

4.  Targeting lysosome function causes selective cytotoxicity in VHL-inactivated renal cell carcinomas.

Authors:  Nadia Bouhamdani; Dominique Comeau; Alexandre Coholan; Kevin Cormier; Sandra Turcotte
Journal:  Carcinogenesis       Date:  2020-07-10       Impact factor: 4.944

5.  Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells.

Authors:  Stefanie Galbán; Jennifer L Martindale; Krystyna Mazan-Mamczarz; Isabel López de Silanes; Jinshui Fan; Wengong Wang; Jochen Decker; Myriam Gorospe
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

6.  Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification.

Authors:  Qiliang Cai; Suhbash C Verma; Pankaj Kumar; Michelle Ma; Erle S Robertson
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

7.  Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL.

Authors:  Vipul C Chitalia; Rebecca L Foy; Markus M Bachschmid; Liling Zeng; Maria V Panchenko; Mina I Zhou; Ajit Bharti; David C Seldin; Stewart H Lecker; Isabel Dominguez; Herbert T Cohen
Journal:  Nat Cell Biol       Date:  2008-09-21       Impact factor: 28.824

8.  Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.

Authors:  W Liu; H Xin; D T Eckert; J A Brown; J R Gnarra
Journal:  Oncogene       Date:  2010-08-30       Impact factor: 9.867

9.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

10.  Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future.

Authors:  John S P Yuen
Journal:  Indian J Urol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.